Sorafekast 200 mg Sorafenib
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Sorafekast 200 mg is an anti-cancer medicine containing sorafenib and belonging to the class of medicines known as tyrosine kinase inhibitors. Its labelling describes it for the treatment of kidney cancer, liver cancer, and thyroid cancer. It is described as working by blocking the function of abnormal protein that signals the multiplication of cancer cells, slowing the growth and further spread of cancer cells. The doctor decides the dose and how often it is used, depending on the patient’s condition.
Product Information
The following description reflects information associated with this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of kidney cancer, liver cancer, and thyroid cancer
- Also listed for pancreatic cancer, breast cancer, small cell and non-small cell lung cancer, blood cancer, gastrointestinal stromal tumour, cancer of the colon and rectum, soft tissue sarcoma, and chronic idiopathic myelofibrosis
- Described as blocking the abnormal protein that signals cancer-cell multiplication, slowing growth and spread
Described Dosage & Administration
- Taken only if advised by a doctor
- The doctor decides the dose and how often it is used, depending on the patient’s condition
- Not to be used without consulting the doctor
Described Side Effects
Commonly described side effects include:
- Fatigue
- Nausea
- Loss of appetite
- Diarrhoea
- Abdominal pain
- Hair loss
- Weight loss
- Rash
- Painful blisters on the hands and feet
Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Described as possibly unsafe for pregnant mothers — a doctor should be consulted before use
- Described as unsafe for breastfeeding mothers, as it may cause toxicity to the baby
- Patients with liver problems are advised to use it with caution
- Described as possibly safe for patients with kidney problems, though a doctor should be consulted first
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical and healthcare products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains sorafenib and is used for the treatment of kidney cancer, liver cancer, and thyroid cancer. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes it as a tyrosine kinase inhibitor that blocks the function of an abnormal protein signalling cancer-cell multiplication, slowing growth and further spread.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.